InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.062 0 (0%)+
Announcement
Release
27 May 2026 9:20AM
Price at Release
$0.062
Full Release
download
Summary
Neurizon Therapeutics Limited, a biotech company focused on neurodegenerative diseases, has announced the expansion of its HEALEY ALS Platform Trial Regimen I from 160 to 240 participants due to a faster-than-expected enrollment rate and no concurrent regimen. This clinical trial aims to maintain statistical power while providing robust subgroup and biomarker analyses. With philanthropic contributions offsetting costs, the expansion is expected to accelerate the trial timeline without increasing overall expenses significantly. The company anticipates dosing the last participant by Q2 CY2027 and releasing topline results by early Q3 CY2027. This expansion is poised to enhance the commercial potential of NUZ-001, Neurizon's lead drug candidate.
Key Points
  • Neurizon Therapeutics Limited expands HEALEY ALS Platform Trial Regimen I to 240 participants.
  • Expansion driven by higher than expected enrollment rate and absence of a concurrent regimen.
  • Regimen I will consist of 180 NUZ-001 participants and 60 placebo controls.
  • Last participant dosing anticipated in Q2 CY2027 with topline results in early Q3 CY2027.
  • Expansion is financially offset by philanthropic funds and expected to have minimal impact on overall trial costs.
  • The larger dataset expected to strengthen partnering and commercial opportunities for NUZ-001.
  • 113 participants assigned and 74 dosed as of 22 May 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.